Pfizer phasing out cholesterol

"A September 25, 2008 memo by Martin Mackay, Pfizer's president for Global Research and Development, confirms that Pfizer will not develop any more drugs that target cholesterol as the culprit in causing heart disease. In fact, Pfizer will exit drug development for cardiovascular disease altogether. Pfizer’s exit from statin development indicates the cholesterol craze has reached the end of its cycle trend. Profits have declined as more statins go off patent, and patients switch to much cheaper generics, or forgo statins altogether in order to take 'essential' medications" - Seeking Alpha